Abstract

Various gene alterations related to acute leukemia are reported to be involved in drug resistance. We investigated idarubicin (IDR) resistance using exome nuclear DNA analyses of the human acute leukemia cell line MOLT-3 and the derived IDR-resistant cell line MOLT-3/IDR. We detected mutations in MOLT-3/IDR and MOLT-3 using both Genome Analysis Toolkit (GATK) and SnpEff program. We found 8839 genes with specific mutations in MOLT-3/IDR and 1162 genes with accompanying amino acid mutations. The 1162 genes were identified by exome analysis of polymerase-related genes using Kyoto Encyclopedia of Genes and Genomes (KEGG) and, among these, we identified genes with amino acid changes. In resistant strains, LIG and helicase plurality genes showed amino-acid-related changes. An amino acid mutation was also confirmed in polymerase-associated genes. Gene ontology (GO) enrichment testing was performed, and lipid-related genes were selected from the results. Fluorescent activated cell sorting (FACS) was used to determine whether IDR permeability was significantly different in MOLT-3/IDR and MOLT-3. The results showed that an IDR concentration of 0.5 μg/mL resulted in slow permeability in MOLT-3/IDR. This slow IDR permeability may be due to the effects of amino acid changes in polymerase- and lipid-associated genes.

Highlights

  • We aimed to characterize the molecular mechanisms underlying idarubicin (IDR) resistance in acute leukemia cells

  • We annotated the detected mutations using SnpEff and compared the mutations detected in MOLT3 and MOLT-3/IDR cells according to the annotated information

  • We investigated the molecular mechanisms underlying IDR resistance using the human T cell leukemia cell line MOLT-3 and its IDR-resistant derivative MOLT-3/IDR

Read more

Summary

Introduction

We aimed to characterize the molecular mechanisms underlying idarubicin (IDR) resistance in acute leukemia cells. It is known that gene alterations in acute leukemia cells are involved in drug resistance. A better understanding of the mechanisms underlying drug resistance in these cells will help to improve the effectiveness of chemotherapy. We investigated the mechanisms underlying drug resistance in the human acute leukemia cell line MOLT-3 and its IDR-resistant derivative MOLT-3/IDR by complete nuclear DNA analyses. The mortality rate of leukemia has been gradually decreasing due to increased bone marrow transplantations; development of antibiotic, antifungal, and antiviral drugs; optimization of transfusion therapy; analysis of treatment protocols by multicenter studies; and development of molecularly targeted drugs [1,2]. IDR, an anthracycline antitumor agent, is used as a therapeutic agent for acute myelogenous leukemia. IDR has been used for acute myeloid leukemia, blast crisis of chronic myelogenous leukemia, and recurrence of acute lymphocytic

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call